Disaggregated Revenues

9 Months Ended

Sep. 30, 2021

Disaggregation of Revenue [Abstract]

Disaggregated Revenues

Disaggregated Revenues

The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):

	Three Months ended September 30,				Nine Months ended September 30,
	2021		2020		2021		2020
	(unaudited)				(unaudited)
Net product sales
Trokendi XR	$	80,935	$	82,906	$	231,531	$	241,131
Oxtellar XR	29,728		28,364		82,120		75,983
APOKYN	24,627		34,482		73,338		43,082
MYOBLOC (1)	4,596		4,050		13,477		5,279
XADAGO	3,276		2,331		9,390		3,132
Qelbree	2,370		—		2,685		—
Total net product sales	$	145,532	$	152,133	$	412,541	$	368,607
Royalty revenues	2,932		3,002		8,184		8,233
Total revenues	$	148,464	$	155,135	$	420,725	$	376,840

______________________________

(1) In April 2021, the Company notified the European Medicines Agency that it will cease the marketing of rimabotulinumtoxinB in European countries where it has been marketed as NeuroBloc.

Trokendi XR accounted for 56% of the Company’s total net product sales for both the three and nine months ended September 30, 2021 and approximately 54% and 65% of the Company's total net product sales for the three and nine months ended September 30, 2020, respectively.

The Company's three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 25% of our total net product sales and collectively accounted for more than 85% of our total net product sales in both 2021 and 2020.

The Company recognized noncash royalty revenue of $2.4 million and $6.8 million, for the three and nine months ended September 30, 2021, respectively. The Company recognized noncash royalty revenue of $2.4 million and $6.3 million, for the three and nine months ended September 30, 2020, respectively. Refer to Note 15, Commitments and Contingencies.